凝固・止血検査市場：検査タイプ、技術、用途別-2025-2030年の世界予測

凝固・止血検査市場は、2023年に52億9,000万米ドルと評価され、2024年には58億8,000万米ドルに達すると予測され、CAGR 11.28％で成長し、2030年には111億8,000万米ドルに達すると予測されています。

凝固・止血検査の範囲と定義には、血液を凝固させ止血バランスを維持する能力を評価するための診断手順と技術が含まれます。この検査は、出血性疾患の特定、抗凝固療法の指導、周術期および重症患者の管理において極めて重要です。その必要性は、血友病、深部静脈血栓症、肺塞栓症の診断、心臓病管理のモニタリングなどの臨床応用にまたがります。エンドユーザーは主に病院、診断検査室、外来外科センターなどです。この市場に影響を与える主な成長要因としては、心血管疾患の有病率の増加、高齢者人口の増加、ポイントオブケア検査技術の進歩、新興国におけるヘルスケアインフラの強化などが挙げられます。最新の潜在機会は、診断精度と効率を高めるための人工知能と機械学習の統合、個別化医療、在宅ヘルスケア環境に対応するポータブル検査機器の開発にあります。しかし、先進的な検査機器の高コスト、厳しい規制当局の承認、発展途上地域における限られた認識といった課題が大きな障害となっています。継続的な技術革新、規制遵守、戦略的パートナーシップに注力することで、こうした制約を緩和することができます。有望な調査・技術革新分野としては、より正確な凝固プロファイルを得るための新規バイオマーカーの探索、技術革新による費用対効果の改善、遠隔医療機能の拡大などが挙げられます。企業は、COVID-19の流行によって加速した遠隔診断や遠隔医療プラットフォームの拡大傾向を利用することで、市場力学に関する洞察を得ることができます。市場の競争は激しく、既存プレーヤーと新興企業が混在し、実質的な研究開発が進められています。事業成長を促進するために、企業は戦略的買収や提携への投資、製品ポートフォリオの強化、未開拓市場への地理的リーチの拡大を検討すべきです。持続的な市場拡大には、技術革新と手頃な価格や入手しやすさのバランスをとることが引き続き重要です。

市場力学：急速に進化する凝固・止血検査市場の主要市場インサイトを公開

凝固・止血検査市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の心血管疾患および血液疾患の有病率の上昇
  • 診断ラボにおける自動止血装置の採用の増加
  • 血友病の啓発に焦点を当てた政府のイニシアチブの利用可能性
• 市場抑制要因
  • 全自動凝固システムに関連する高コスト
• 市場機会
  • ポイントオブケア（POC）凝固検査に対する需要の高まり
  • 凝固・止血検査における技術の進歩
• 市場の課題
  • 厳しく時間のかかる規制プロセス

ポーターの5つの力：凝固・止血検査市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、凝固・止血検査市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：凝固・止血検査市場における外部からの影響の把握

外部マクロ環境要因は、凝固・止血検査市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析凝固・止血検査市場における競合情勢の把握

凝固・止血検査市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス凝固・止血検査市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、凝固・止血検査市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨凝固・止血検査市場における成功への道筋を描く

凝固・止血検査市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界的に心血管疾患と血液疾患の罹患率が上昇
    • 診断検査室における自動止血装置の導入増加
    • 血友病の啓発に重点を置いた政府の取り組みの有無
  • 抑制要因
    • 完全自動化凝固システムに伴う高コスト
  • 機会
    • ポイントオブケア（POC）凝固検査の需要増加
    • 凝固・止血検査における技術的進歩
  • 課題
    • 厳格で時間のかかる規制プロセス
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 凝固・止血検査市場テストタイプ別

• 活性化部分トロンボプラスチン時間
• Dダイマー検査
• フィブリノーゲン検査
• 血小板機能検査

第7章 凝固・止血検査市場：技術別

• 電気化学技術
• 機械技術
• 光学技術

第8章 凝固・止血検査市場：最終用途別

• 診断センター
• 病院
• ポイントオブケア検査

第9章 南北アメリカの凝固・止血検査市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の凝固・止血検査市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの凝固・止血検査市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Danaher Corporation
• Diagnostica Stago SAS
• F. Hoffmann-La Roche Ltd.
• George King Bio-Medical, Inc.
• Grifols, S.A.
• Helena Laboratories Corporation
• Medtronic PLC
• Micropoint Biotechnologies Co., Ltd
• Sekisui Chemical Co., Ltd.
• Siemens AG
• Sysmex Corporation
• Tcoag Ireland Limited
• Thermo Fisher Scientific Inc.
• Werfen, S.A.

LIST OF FIGURES

• FIGURE 1. COAGULATION & HEMOSTASIS TESTING MARKET RESEARCH PROCESS
• FIGURE 2. COAGULATION & HEMOSTASIS TESTING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. COAGULATION & HEMOSTASIS TESTING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. COAGULATION & HEMOSTASIS TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. COAGULATION & HEMOSTASIS TESTING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. COAGULATION & HEMOSTASIS TESTING MARKET DYNAMICS
• TABLE 7. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY ACTIVATED PARTIAL THROMBOPLASTIN TIME, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY D-DIMER TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY FIBRINOGEN TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY PLATELET FUNCTION TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY ELECTROCHEMICAL TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY MECHANICAL TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY OPTICAL TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY POINT-OF-CARE TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 30. CANADA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 31. CANADA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 32. CANADA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 47. CHINA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 48. CHINA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 49. CHINA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 50. INDIA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 51. INDIA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 52. INDIA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 102. ITALY COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 103. ITALY COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 104. ITALY COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 114. POLAND COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 115. POLAND COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 116. POLAND COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 117. QATAR COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 118. QATAR COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 119. QATAR COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM COAGULATION & HEMOSTASIS TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 147. COAGULATION & HEMOSTASIS TESTING MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 148. COAGULATION & HEMOSTASIS TESTING MARKET, FPNV POSITIONING MATRIX, 2023

The Coagulation & Hemostasis Testing Market was valued at USD 5.29 billion in 2023, expected to reach USD 5.88 billion in 2024, and is projected to grow at a CAGR of 11.28%, to USD 11.18 billion by 2030.

The scope and definition of coagulation and hemostasis testing encompass diagnostic procedures and technologies used to evaluate the blood's ability to clot and maintain hemostatic balance. This testing is crucial in identifying bleeding disorders, guiding anticoagulant therapy, and managing perioperative and critical care patients. Its necessity spans across clinical applications such as diagnosing hemophilia, deep vein thrombosis, pulmonary embolism, and monitoring heart disease management. End-users primarily include hospitals, diagnostic laboratories, and outpatient surgical centers. Key growth factors influencing this market include the increasing prevalence of cardiovascular diseases, rising elderly population, advancements in technology with point-of-care testing, and enhanced healthcare infrastructure in emerging economies. The latest potential opportunities lie in the integration of artificial intelligence and machine learning to enhance diagnostic accuracy and efficiency, personalized medicine, and the development of portable testing devices that cater to home healthcare settings. However, challenges such as high cost of advanced testing equipment, stringent regulatory approvals, and limited awareness in developing regions pose significant hurdles. A focus on continuous innovation, regulatory compliance, and strategic partnerships can mitigate these limitations. Promising areas of research and innovation include the exploration of novel biomarkers for more precise coagulation profiles, improving cost-effectiveness through technological innovations, and expanding telemedicine capabilities. Businesses can gain insights into market dynamics by tapping into the growing trend of remote diagnostics and telehealth platforms, which were accelerated by the COVID-19 pandemic. The nature of the market is highly competitive with a mix of established players and startups driving substantial research and development. To foster business growth, companies should consider investing in strategic acquisitions or collaborations, enhancing product portfolios, and expanding geographical reach to underserved markets. Balancing technological innovation with affordability and accessibility remains crucial for sustained market expansion.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Coagulation & Hemostasis Testing Market

The Coagulation & Hemostasis Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rise in the Prevalence of cardiovascular diseases and blood disorders globally
  • Increasing adoption of automated hemostasis equipment in diagnostic laboratories
  • Availability of government initiatives focusing on awareness of hemophilia
• Market Restraints
  • High cost associated with fully automated coagulation systems
• Market Opportunities
  • Rising demand for point of care (POC) coagulation testing
  • Technological advancements in coagulation & hemostasis testing
• Market Challenges
  • Stringent and time-consuming regulatory processes

Porter's Five Forces: A Strategic Tool for Navigating the Coagulation & Hemostasis Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Coagulation & Hemostasis Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Coagulation & Hemostasis Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Coagulation & Hemostasis Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Coagulation & Hemostasis Testing Market

A detailed market share analysis in the Coagulation & Hemostasis Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Coagulation & Hemostasis Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Coagulation & Hemostasis Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Coagulation & Hemostasis Testing Market

A strategic analysis of the Coagulation & Hemostasis Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Coagulation & Hemostasis Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Danaher Corporation, Diagnostica Stago SAS, F. Hoffmann-La Roche Ltd., George King Bio-Medical, Inc., Grifols, S.A., Helena Laboratories Corporation, Medtronic PLC, Micropoint Biotechnologies Co., Ltd, Sekisui Chemical Co., Ltd., Siemens AG, Sysmex Corporation, Tcoag Ireland Limited, Thermo Fisher Scientific Inc., and Werfen, S.A..

Market Segmentation & Coverage

This research report categorizes the Coagulation & Hemostasis Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Test Type, market is studied across Activated Partial Thromboplastin Time, D-Dimer Testing, Fibrinogen Testing, and Platelet Function Tests.
• Based on Technology, market is studied across Electrochemical Technology, Mechanical Technology, and Optical Technology.
• Based on End-Use, market is studied across Diagnostic Centers, Hospitals, and Point-of-Care Testing.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rise in the Prevalence of cardiovascular diseases and blood disorders globally
    • 5.1.1.2. Increasing adoption of automated hemostasis equipment in diagnostic laboratories
    • 5.1.1.3. Availability of government initiatives focusing on awareness of hemophilia
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated with fully automated coagulation systems
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising demand for point of care (POC) coagulation testing
    • 5.1.3.2. Technological advancements in coagulation & hemostasis testing
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent and time-consuming regulatory processes
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Coagulation & Hemostasis Testing Market, by Test Type

• 6.1. Introduction
• 6.2. Activated Partial Thromboplastin Time
• 6.3. D-Dimer Testing
• 6.4. Fibrinogen Testing
• 6.5. Platelet Function Tests

7. Coagulation & Hemostasis Testing Market, by Technology

• 7.1. Introduction
• 7.2. Electrochemical Technology
• 7.3. Mechanical Technology
• 7.4. Optical Technology

8. Coagulation & Hemostasis Testing Market, by End-Use

• 8.1. Introduction
• 8.2. Diagnostic Centers
• 8.3. Hospitals
• 8.4. Point-of-Care Testing

9. Americas Coagulation & Hemostasis Testing Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Coagulation & Hemostasis Testing Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Coagulation & Hemostasis Testing Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Danaher Corporation
• 3. Diagnostica Stago SAS
• 4. F. Hoffmann-La Roche Ltd.
• 5. George King Bio-Medical, Inc.
• 6. Grifols, S.A.
• 7. Helena Laboratories Corporation
• 8. Medtronic PLC
• 9. Micropoint Biotechnologies Co., Ltd
• 10. Sekisui Chemical Co., Ltd.
• 11. Siemens AG
• 12. Sysmex Corporation
• 13. Tcoag Ireland Limited
• 14. Thermo Fisher Scientific Inc.
• 15. Werfen, S.A.